Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tocilizumab for Refractory Anti-Synthetase Syndrome-Associated Interstitial Lung Disease: A Real-World Retrospective Cohort Study

NCT07662265 is registered in ClinicalTrials.gov with Hu Yinan as lead sponsor.

NCT NCT07662265
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07662265 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tocilizumab for Refractory Anti-Synthetase Syndrome-Associated Interstitial Lung Disease: A Real-World Retrospective Cohort Study
Lead sponsor
Hu Yinan
Phase
Observational
Overall status
Completed
Start date
January 1, 2022
Completion date
October 31, 2025
Enrollment
111 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antisynthetase syndrome, tocilizumab